About Us

Equillium is a clinical-stage biopharmaceutical company developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab has potential to be a best-in-class disease-modifying therapeutic and is currently being evaluated in clinical trials in multiple indications, including acute graft-versus-host disease, uncontrolled asthma, and SLE / lupus nephritis.

Learn More

Executive Team

Bruce Steel, CFA

Chief Executive Officer

Stephen Connelly, Ph.D.

Chief Scientific Officer

Krishna Polu, M.D.

Chief Medical Officer

Jason Keyes

Chief Financial Officer

Christine Zedelmayer, PMP

Chief Operating Officer

Joel Rothman

SVP of Development Operations

Board of Directors

Daniel Bradbury

Executive Chairman

Bruce Steel, CFA

Chief Executive Officer

Stephen Connelly, Ph.D.

Chief Scientific Officer

Bala Manian, Ph.D.

Director

Mark Pruzanski, M.D.

Director

Charles McDermott

Director

Martha Demski

Director

Scientific and Clinical Advisors

Siddhartha Mukherjee, MD, Ph.D.

Tom Daniel, M.D.

Brian Kotzin, M.D.

Larry Steinman, M.D.

Vijay Kuchroo, D.V.M., Ph.D.

Fred Ramsdell, Ph.D.

Pradip Nair, Ph.D.

Partners

Equillium acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.